Ahmed Alanazi: ASCO25 Plenary Session on ATOMIC Trial Results in Stage III Colon Cancer

Ahmed Alanazi, Department Program Director at King Fahad Medical City, shared a post on X:

“ASCO25 Plenary Session ATOMIC phase3 multi-center randomized open label clinical trial of adjuvant ATEZO+mFOLFOX vs mFOLFOX in resected stage III dMMR/MSI-H R0 colon cancer patients

– 3-years DFS 86.4% vs 76.6% HR 0.50
– OS data still immature
– Grade 3/4 weren’t siginficant betwen the two group
– most common irAE no new concerns
– Neutropenia was increased among atezo group.”

ASCO25

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

Highlights from ASCO 2025 Day 3

ASCO

Blog Posts

Ahmed Alanazi ASCO ASCO 2025 ASCO25 ATOMIC trial cancer Colon cancer OncoDaily Oncology

Ahmed Alanazi: ASCO25 Plenary Session on ATOMIC Trial Results in Stage III Colon Cancer

“ASCO25 Plenary Session ATOMIC phase3 multi-center randomized open label clinical trial of adjuvant ATEZO+mFOLFOX vs mFOLFOX in resected stage III dMMR/MSI-H R0 colon cancer patients

– 3-years DFS 86.4% vs 76.6% HR 0.50 – OS data still immature – Grade 3/4 weren’t siginficant betwen the two group – most common irAE no new concerns – Neutropenia was increased among atezo group.”

– 3-years DFS 86.4% vs 76.6% HR 0.50
– OS data still immature
– Grade 3/4 weren’t siginficant betwen the two group
– most common irAE no new concerns
– Neutropenia was increased among atezo group.”